{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:32:43Z","timestamp":1787020363016,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The escalating prevalence of adrenal incidentaloma (AI) has been associated with the improvement of radiologic techniques and widespread imaging in aging population. It is currently unclear whether patients with obesity more likely develop AI and the current rise in the prevalence of AI could be at least partly associated with the respective rise in obesity. We compared the prevalence and characteristics of non-functional (NF) and autonomous cortisol secreting (ACS) adrenal incidentalomas (AIs) after the study population was stratified by different body mass indexes (BMI) and age groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Retrospective cross-sectional study comprising of 432 patients (40.6% male, 59.4% female) with NFAI (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009290) and ACS (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009142), of median age 63.4 (54.0\u201371.6) years and median BMI 28.6 (25.5\u201331.7) kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . The data collection contained 11.132 points including demographic, anthropometric, radiologic, hormonal and metabolic parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We observed 68\u201387% higher prevalence of AI across different age groups in NFAI and ACS in obese\/overweight compared to normal weight subjects. Patients with ACS were older (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.008), with higher basal cortisol (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), lower basal DHEAS (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001), lower suppression DHEAS (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.027) and higher aldosterone (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.039). AIs with ACS were larger than NFAI (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Interestingly, ACS group had lower body mass (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.023) and did not differ in BMI, blood pressure, heart rate, lipid profile, fasting glucose and presence of diabetes mellitus type 2 when compared to NFAI., By contrast to the similarity of metabolic profiles in ACS and NFAI, some components of adverse metabolic traits were rather associated with higher BMI and older age, in particular in NFAI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The prevalence of NFAI and ACS were significantly higher in overweight\/obese subgroup across the age distribution. Stratification by age and BMI displayed significant differences in some metabolic traits, in particular in NFAI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-020-00599-0","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T08:03:58Z","timestamp":1596182638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patients\u2019 stratification by body mass index and age"],"prefix":"10.1186","volume":"20","author":[{"given":"Ana","family":"Podbregar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Janez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Goricar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Jensterle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"issue":"2","key":"599_CR1","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0467","volume":"175","author":"M Fassnacht","year":"2016","unstructured":"Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2016;175(2):G1\u2013G34.","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"599_CR2","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/jcp.2006.044313","volume":"61","author":"PK Singh","year":"2008","unstructured":"Singh PK, Buch HN. Adrenal incidentaloma: evaluation and management. J Clin Pathol. 2008;61(11):1168\u201373.","journal-title":"J Clin Pathol"},{"key":"599_CR3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1758-5996-2-71","volume":"2","author":"N Hiroi","year":"2010","unstructured":"Hiroi N, Sue M, Yoshihara A, Ichijo T, Yoshida-Hiroi M, Higa M, et al. Prevalence of adrenal masses in Japanese patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2010;2:71.","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"599_CR4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/BF03344099","volume":"29","author":"S Bovio","year":"2006","unstructured":"Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006;29(4):298\u2013302.","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"599_CR5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrendo.2011.92","volume":"7","author":"DA Vassiliadi","year":"2011","unstructured":"Vassiliadi DA, Tsagarakis S. Endocrine incidentalomas--challenges imposed by incidentally discovered lesions. Nat Rev Endocrinol. 2011;7(11):668\u201380.","journal-title":"Nat Rev Endocrinol"},{"key":"599_CR6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.maturitas.2016.07.017","volume":"92","author":"SA Paschou","year":"2016","unstructured":"Paschou SA, Vryonidou A, Goulis DG. Adrenal incidentalomas: a guide to assessment, treatment and follow-up. Maturitas. 2016;92:79\u201385.","journal-title":"Maturitas."},{"key":"599_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.maturitas.2018.12.002","volume":"121","author":"GI Sydney","year":"2019","unstructured":"Sydney GI, Ioakim KJ, Paschou SA. Insulin resistance and adrenal incidentalomas: a bidirectional relationship. Maturitas. 2019;121:1\u20136.","journal-title":"Maturitas."},{"issue":"6","key":"599_CR8","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1210\/en.2016-1804","volume":"158","author":"G Muscogiuri","year":"2017","unstructured":"Muscogiuri G, De Martino MC, Negri M, Pivonello C, Simeoli C, Orio F, et al. Adrenal mass: insight into pathogenesis and a common link with insulin resistance. Endocrinology. 2017;158(6):1527\u201332.","journal-title":"Endocrinology."},{"issue":"4","key":"599_CR9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1530\/EJE-09-0234","volume":"161","author":"TJ Cawood","year":"2009","unstructured":"Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. 2009;161(4):513\u201327.","journal-title":"Eur J Endocrinol"},{"key":"599_CR10","doi-asserted-by":"crossref","unstructured":"Cyranska-Chyrek E, Szczepanek-Parulska E, Olejarz M, Ruchala M. Malignancy risk and hormonal activity of adrenal Incidentalomas in a large cohort of patients from a single tertiary reference center. Int J Environ Res Public Health. 2019;16(10):1872.","DOI":"10.3390\/ijerph16101872"},{"issue":"4","key":"599_CR11","doi-asserted-by":"crossref","first-page":"M61","DOI":"10.1530\/EJE-15-0272","volume":"173","author":"G Di Dalmazi","year":"2015","unstructured":"Di Dalmazi G, Pasquali R, Beuschlein F, Reincke M. Subclinical hypercortisolism: a state, a syndrome, or a disease? Eur J Endocrinol. 2015;173(4):M61\u201371.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"599_CR12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMcp065470","volume":"356","author":"WF Young Jr","year":"2007","unstructured":"Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601\u201310.","journal-title":"N Engl J Med"},{"issue":"5","key":"599_CR13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/cen.13822","volume":"89","author":"EM Ribeiro Cavalari","year":"2018","unstructured":"Ribeiro Cavalari EM, de Paula MP, Arruda M, Carraro N, Martins A, de Souza K, et al. Nonfunctioning adrenal incidentaloma: a novel predictive factor for metabolic syndrome. Clin Endocrinol (Oxf). 2018;89(5):586\u201395.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"599_CR14","first-page":"1440","volume":"85","author":"R Rossi","year":"2000","unstructured":"Rossi R, Tauchmanova L, Luciano A, Di Martino M, Battista C, Del Viscovo L, et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab. 2000;85(4):1440\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"599_CR15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40618-018-0985-y","volume":"42","author":"AB Moraes","year":"2019","unstructured":"Moraes AB, Cavalari EMR, de Paula MP, Arruda M, Curi DSC, Leitao RA, et al. Evaluation of body composition using dual-energy X-ray absorptiometry in patients with non-functioning adrenal incidentalomas and an intermediate phenotype: is there an association with metabolic syndrome? J Endocrinol Invest. 2019;42(7):797\u2013807.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"599_CR16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2214\/ajr.171.1.9648789","volume":"171","author":"GW Boland","year":"1998","unstructured":"Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998;171(1):201\u20134.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"599_CR17","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2214\/ajr.175.5.1751411","volume":"175","author":"EM Caoili","year":"2000","unstructured":"Caoili EM, Korobkin M, Francis IR, Cohan RH, Dunnick NR. Delayed enhanced CT of lipid-poor adrenal adenomas. AJR Am J Roentgenol. 2000;175(5):1411\u20135.","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"599_CR18","doi-asserted-by":"crossref","first-page":"W706","DOI":"10.2214\/AJR.10.5540","volume":"196","author":"N Bharwani","year":"2011","unstructured":"Bharwani N, Rockall AG, Sahdev A, Gueorguiev M, Drake W, Grossman AB, et al. Adrenocortical carcinoma: the range of appearances on CT and MRI. AJR Am J Roentgenol. 2011;196(6):W706\u201314.","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"599_CR19","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s00268-014-2524-0","volume":"38","author":"C Sadler","year":"2014","unstructured":"Sadler C, Goldfarb M. Risk estimator for adrenal tumor functionality. World J Surg. 2014;38(8):2019\u201324.","journal-title":"World J Surg"},{"issue":"5","key":"599_CR20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1530\/EJE-17-0986","volume":"178","author":"E Sbardella","year":"2018","unstructured":"Sbardella E, Minnetti M, D'Aluisio D, Rizza L, Di Giorgio MR, Vinci F, et al. Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas. Eur J Endocrinol. 2018;178(5):501\u201311.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"599_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12020-019-01888-y","volume":"64","author":"M Araujo-Castro","year":"2019","unstructured":"Araujo-Castro M, Sampedro Nunez MA, Marazuela M. Autonomous cortisol secretion in adrenal incidentalomas. Endocrine. 2019;64(1):1\u201313.","journal-title":"Endocrine."},{"issue":"3","key":"599_CR22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1210\/jcem.87.3.8277","volume":"87","author":"M Terzolo","year":"2002","unstructured":"Terzolo M, Pia A, Ali A, Osella G, Reimondo G, Bovio S, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002;87(3):998\u20131003.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"599_CR23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/07435809609043773","volume":"22","author":"M Reincke","year":"1996","unstructured":"Reincke M, Fassnacht M, Vath S, Mora P, Allolio B. Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocr Res. 1996;22(4):757\u201361.","journal-title":"Endocr Res"},{"issue":"6","key":"599_CR24","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1046\/j.1365-2265.2001.01274.x","volume":"54","author":"S Midorikawa","year":"2001","unstructured":"Midorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T. The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol (Oxf). 2001;54(6):797\u2013804.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"599_CR25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1365-2265.2010.03928.x","volume":"74","author":"G Muscogiuri","year":"2011","unstructured":"Muscogiuri G, Sorice GP, Prioletta A, Mezza T, Cipolla C, Salomone E, et al. The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause-effect relationship? Clin Endocrinol (Oxf). 2011;74(3):300\u20135.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"599_CR26","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s12020-019-02066-w","volume":"66","author":"M Araujo-Castro","year":"2019","unstructured":"Araujo-Castro M, Robles Lazaro C, Parra Ramirez P, Cuesta Hernandez M, Sampedro Nunez MA, Marazuela M. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences? Endocrine. 2019;66(3):650\u20139.","journal-title":"Endocrine."},{"issue":"4","key":"599_CR27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/eje.0.1490273","volume":"149","author":"L Barzon","year":"2003","unstructured":"Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003;149(4):273\u201385.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"599_CR28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.7326\/0003-4819-138-5-200303040-00013","volume":"138","author":"MM Grumbach","year":"2003","unstructured":"Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, et al. Management of the clinically inapparent adrenal mass (\"incidentaloma\"). Ann Intern Med. 2003;138(5):424\u20139.","journal-title":"Ann Intern Med"},{"issue":"2","key":"599_CR29","first-page":"637","volume":"85","author":"F Mantero","year":"2000","unstructured":"Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, et al. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian society of endocrinology. J Clin Endocrinol Metab. 2000;85(2):637\u201344.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"599_CR30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2265.2010.03794.x","volume":"73","author":"V Morelli","year":"2010","unstructured":"Morelli V, Masserini B, Salcuni AS, Eller-Vainicher C, Savoca C, Viti R, et al. Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol (Oxf). 2010;73(2):161\u20136.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"599_CR31","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1210\/jc.2010-2722","volume":"96","author":"I Chiodini","year":"2011","unstructured":"Chiodini I. Clinical review: diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011;96(5):1223\u201336.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"599_CR32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12020-015-0776-6","volume":"51","author":"SA Paschou","year":"2016","unstructured":"Paschou SA, Kandaraki E, Dimitropoulou F, Goulis DG, Vryonidou A. Subclinical Cushing's syndrome in patients with bilateral compared to unilateral adrenal incidentalomas: a systematic review and meta-analysis. Endocrine. 2016;51(2):225\u201335.","journal-title":"Endocrine."},{"issue":"3","key":"599_CR33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/jclinpath-2014-202612","volume":"68","author":"K Duan","year":"2015","unstructured":"Duan K, Gomez Hernandez K, Mete O. Clinicopathological correlates of adrenal Cushing's syndrome. J Clin Pathol. 2015;68(3):175\u201386.","journal-title":"J Clin Pathol"},{"key":"599_CR34","doi-asserted-by":"crossref","unstructured":"Tsatsoulis A. The role of insulin resistance\/Hyperinsulinism on the rising trend of thyroid and adrenal nodular disease in the current environment. J Clin Med. 2018;7(3):37.","DOI":"10.3390\/jcm7030037"},{"key":"599_CR35","doi-asserted-by":"crossref","unstructured":"Arlt W, Lang K, Sitch AJ, Dietz AS, Rhayem Y, Bancos I, et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight. 2017;2(8):e93136.","DOI":"10.1172\/jci.insight.93136"},{"issue":"3","key":"599_CR36","first-page":"786","volume":"102","author":"MC Dennedy","year":"2017","unstructured":"Dennedy MC, Annamalai AK, Prankerd-Smith O, Freeman N, Vengopal K, Graggaber J, et al. Low DHEAS: a sensitive and specific test for the detection of subclinical Hypercortisolism in adrenal Incidentalomas. J Clin Endocrinol Metab. 2017;102(3):786\u201392.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-020-00599-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-020-00599-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-020-00599-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T00:05:35Z","timestamp":1723334735000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-020-00599-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["599"],"URL":"https:\/\/doi.org\/10.1186\/s12902-020-00599-0","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]},"assertion":[{"value":"2 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Republic of Slovenia National Medical Ethics Committee, the reference number 0120\u2013134\/2019. In accordance with the Institutional policy informed written consent from each patient was not needed due to retrospective non-interventional nature of the study. We processed personal date in accordance with the general regulation on the protection of personal data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"\u201cNot applicable.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}